Real-world Clinical Effectiveness of Guselkumab and Its Impact on Quality of Life and Sexual Quality of Life in Patients with Genital Psoriasis: Results from the CASSIOPEE Study
Clicks: 4
ID: 321790
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
4 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #64 of 296 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 296 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Guselkumab demonstrated marked real-world effectiveness in improving clinical, psychosocial, and sexual outcomes among patients with moderate-to-severe plaque psoriasis, including those with genital involvement. In the multicentre CASSIOPEE study, over 90% of patients with genital psoriasis achieved skin clearance at six months, accompanied by substantial gains in quality of life and sexual well-being. These findings highlight the broad patient-reported benefits of guselkumab beyond skin symptoms.
| Reference Key |
openalex_W7169836189
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Marie-Aleth Richard, C Bulai Livideanu, Anne-Claire Fougerousse, Delphine Staumont-Sallé, Julie Baraut, Samira Chaalal, Raphaëlle Parker, L. Misery |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag291
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.